Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients

Open-label Study to Evaluate the Effects of Once Daily Extraneal (7.5% Icodextrin) Peritoneal Dialysis Solution on Triglyceride Levels in Peritoneal Dialysis Patients

This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients.

This prospective, open label, multi-center study evaluates the use of 7.5% icodextrin used in the long-dwell exchange in peritoneal dialysis patients with elevated triglyceride levels. Fasting triglyceride levels will be measured during the study.

Inclusion Criteria:

• written informed consent
• CAPD/APD on dialysis for at least 3 months
• Elevated fasting triglyceride levels

Exclusion Criteria:

• enrolled in another study requiring IRB approval
• allergy to starch-based polymers
• glycogen storage disease
• maltose or isomaltose intolerance
• active alcohol/substance abuse
• Pregnant or nursing
• received an investigational drug within 30 days of screening